Antimicrobial activity of dalbavancin against clinical isolates of coagulase-negative staphylococci from the USA and Europe stratified by species
Open Access
- 4 December 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Global Antimicrobial Resistance
- Vol. 24, 48-52
- https://doi.org/10.1016/j.jgar.2020.11.020
Abstract
No abstract availableKeywords
Funding Information
- Allergan Foundation
- AbbVie
This publication has 20 references indexed in Scilit:
- Staphylococcal species less frequently isolated from human clinical specimens - are they a threat for hospital patients?BMC Infectious Diseases, 2020
- Coagulase-Negative Staphylococci PathogenomicsInternational Journal of Molecular Sciences, 2019
- Prosthetic Joint Infection UpdateInfectious Disease Clinics of North America, 2018
- Are coagulase-negative staphylococci virulent?Clinical Microbiology & Infection, 2018
- Is Staphylococcus lugdunensis Significant in Clinical Samples?Journal of Clinical Microbiology, 2017
- Clinical significance of coagulase-negative staphylococci other than S. epidermidis blood stream isolates at a tertiary care hospitalInfection, 2016
- Coagulase-Negative StaphylococciClinical Microbiology Reviews, 2014
- Microbiological and Molecular Characterization of Staphylococcus hominis Isolates from BloodPLOS ONE, 2013
- Microbiological Aetiology, Epidemiology, and Clinical Profile of Prosthetic Joint Infections: Are Current Antibiotic Prophylaxis Guidelines Effective?Antimicrobial Agents and Chemotherapy, 2012
- Glycopeptide Resistance in Coagulase-Negative StaphylococciEuropean Journal of Clinical Microbiology & Infectious Diseases, 2000